Novartis: multiple sclerosis drug has positive impact
(CercleFinance.com) - Treatment with Mayzent had a clinically meaningful positive impact on cognitive processing speed in patients with secondary progressive multiple sclerosis, the Swiss drugmaker said on Wednesday.
Phase III data also showed that patients treated earlier in the course of their disease with less cognitive impairment benefited the most from Mayzent treatment compared to placebo, Novartis said.
Mayzent's regulatory filing in the European Union is expected in late 2019, the company said.
Novartis also said that long-term follow-up data from a Phase 1 trial of its investigational drug Zolgensma showed durability of the gene therapy in patients with spinal muscular atrophy nearly four years after treatment.
Separataly, Novartis unveiled results from a study on its algorithm-based digital solution MSProDiscuss that facilitates discussions between physicians and patients with multiple sclerosis.
Copyright (c) 2019 CercleFinance.com. All rights reserved.